IDYA - CIK 0001676725
IDEAYA Biosciences, Inc. trades as IDYA and has a market capitalization of $2.40 B, making it the #1971 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $218.71M, up 3024.4% from the prior year and net income of -$113.70M. This page tracks IDEAYA Biosciences, Inc. through 477 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -176.6% to -52.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-05 |
| Prospectus supplement | 424B5 | 2026-05-05 |
| S-3ASR | - | 2026-05-05 |
| Quarterly report | 10-Q | 2026-05-05 |
| Major company event | 8-K | 2026-05-05 |
| Proxy materials | DEFA14A | 2026-04-30 |
| Proxy statement | DEF 14A | 2026-04-29 |
IDEAYA Biosciences is a precision medicine oncology company committed to the discovery, development, and commercialization of targeted therapeutics for patient populations selected using molecular diagnostics.
IDEAYA Biosciences is a precision medicine oncology company committed to the discovery, development, and commercialization of targeted therapeutics for patient populations selected using molecular diagnostics.
IDEAYA Biosciences is a precision medicine oncology company committed to the discovery, development, and commercialization of targeted therapeutics for patient populations selected using molecular diagnostics.
IDEAYA Biosciences is a precision medicine oncology company committed to the discovery, development, and commercialization of targeted therapeutics for patient populations selected using molecular diagnostics.
The largest companies sharing IDEAYA Biosciences, Inc.'s SEC industry classification (pharmaceutical preparations).
IDEAYA Biosciences, Inc. (IDYA) has a market capitalization of $2.40 B as of 2026-06-10, ranking #1971 among US-listed companies.
IDEAYA Biosciences, Inc. reported revenue of $218.71M for fiscal year 2025, an increase of 3024.4% year over year.
In its latest fiscal year IDEAYA Biosciences, Inc. reported a net loss of $113.70M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
IDEAYA Biosciences is a precision medicine oncology company committed to the discovery, development, and commercialization of targeted therapeutics for patient populations selected using molecular diagnostics.